Europe Breast Cancer Screening Market Forecast 2025–2033

Europe Breast Cancer Screening Market Size and Forecast 2025-2033

Europe Breast Cancer Screening Market was valued at USD 1.12 billion in 2024 and is predicted to reach USD 2.43 billion by 2033, growing at a CAGR of 9.02% from 2025 to 2033. The market is driven by increasing awareness about early cancer detection, advancements in screening technologies, and government initiatives promoting regular breast cancer screenings. The rising prevalence of breast cancer and improved access to healthcare facilities further contribute to market growth.

The report Europe Breast Cancer Screening Market & Forecast covers by Application (Mammography Screening, MRI Screening, Ultrasound Screening), Population (Mammography Screening Population, MRI & Ultrasound Screening Population), Country and Company Analysis 2025-2033.

Europe Breast Cancer Screening Market Overview

Breast cancer screening involves medical tests and imaging techniques to detect breast cancer at an early stage, often before symptoms appear. The most common screening methods include mammography, ultrasound, MRI, and genetic testing for high-risk individuals. Early detection significantly improves treatment success rates and survival rates by enabling timely interventions.

In Europe, breast cancer screening programs are widely promoted by governments and healthcare organizations. Many countries have national screening programs offering routine mammograms for women over a certain age, typically 50 to 74 years. The popularity of screening has grown due to increasing awareness, better healthcare infrastructure, and technological advancements. With the rise in breast cancer cases, European countries continue to expand access to screening, ensuring more women undergo regular check-ups. AI-assisted mammography and portable screening devices are enhancing early detection capabilities. As awareness and accessibility improve, the demand for advanced screening techniques continues to rise across Europe.

Growth Drivers in the Europe Breast Cancer Screening Market

Government Initiatives and Awareness Programs

 European governments actively promote breast cancer screening through national programs and awareness campaigns. Countries like the UK, Germany, and France offer free or subsidized mammograms for women aged 50-74. Organizations such as the European Breast Cancer Coalition advocate for early detection, ensuring increased participation in screening programs. These initiatives help drive demand for screening services and technologies, leading to market expansion. The EU is actively combating breast cancer through its Beating Cancer Plan, part of the European Health Union strategy. In 2022, updated screening guidelines for breast, colorectal, and cervical cancer were adopted, aiming to offer screening to 90% of eligible populations across the EU for improved prevention, treatment, and quality of life.

Advancements in Screening Technologies

The adoption of digital mammography, AI-driven diagnostics, and 3D tomosynthesis has improved early breast cancer detection. AI-powered imaging systems enhance accuracy, reducing false positives and negatives. Europe is at the forefront of integrating these innovations into routine screenings, making advanced methods more accessible. As hospitals and diagnostic centers upgrade their equipment, the demand for cutting-edge screening technologies continues to rise. Mar 2025, GE HealthCare launched Invenia™ Automated Breast Ultrasound (ABUS) Premium, a 3D ultrasound featuring advanced AI to enhance supplemental screening and streamline exam readings for patients with dense breasts.

Rising Breast Cancer Incidence Rates

With increasing breast cancer cases across Europe, there is growing urgency for widespread screening programs. The European Cancer Information System (ECIS) reports that breast cancer remains the most common cancer among women in Europe. The aging population and lifestyle factors contribute to higher risk, making routine screening essential. This demand fuels investments in screening infrastructure and services. Breast cancer is the most common cancer in women in the WHO Europe region with an estimated incidence of 604,900 in 2022.

Challenges in the Europe Breast Cancer Screening Market

High Cost of Advanced Screening Technologies

Despite advancements, the high cost of MRI and 3D mammography remains a barrier. Not all healthcare facilities can afford the latest screening equipment, limiting access in some regions. In countries with underfunded healthcare systems, affordability issues prevent widespread adoption of advanced screening methods, leading to disparities in early detection.

Screening Coverage Gaps and Accessibility Issues

Rural and underserved areas in Europe face challenges in accessing breast cancer screening. While urban centers have well-established programs, remote areas often lack the necessary healthcare infrastructure. Mobile screening units and telemedicine solutions are emerging to bridge the gap, but disparities still exist, particularly in Eastern Europe.

Europe Breast Cancer Screening Population Market

The growing population of women eligible for breast cancer screening drives market growth. With an increasing focus on preventive healthcare, governments and private healthcare providers are expanding screening programs to cover younger women at high risk. Personalized risk assessments and genetic screening for BRCA1 and BRCA2 mutations are becoming more prevalent, improving early detection rates.

Europe Breast Cancer Mammography Screening Market

Mammography remains the gold standard for breast cancer screening in Europe. The market is expanding due to rising government investments in screening infrastructure. Digital mammography and 3D tomosynthesis offer higher accuracy, leading to increased adoption. Many European countries conduct nationwide mammography screening, improving early diagnosis rates.

Europe Breast Cancer MRI Screening Market

MRI is increasingly used for high-risk patients and dense breast tissue cases. Europe has seen rising adoption of breast MRI due to its superior sensitivity in detecting early-stage tumors. However, the high cost and limited availability of MRI machines restrict widespread use, primarily benefiting those with private healthcare access.

Europe Breast Cancer Ultrasound Screening Market

Ultrasound is widely used as a supplementary screening method, especially for women with dense breast tissue. European healthcare systems are integrating automated breast ultrasound (ABUS) to improve screening accuracy. Ultrasound is particularly beneficial in cases where mammograms may be less effective, driving demand across hospitals and diagnostic centers.

Germany Breast Cancer Screening Market

Germany has one of the most well-established breast cancer screening programs in Europe. The country offers nationwide mammography screening for women aged 50-69, funded by statutory health insurance. Technological advancements and AI-driven diagnostics are boosting the German market, making screenings more efficient and accessible. Feb 2023, Germany's deep tech startup Vara has recruited renowned radiologist Professor Katja Pinker-Domenig as its lead medical advisor to provide women worldwide with access to improved breast cancer screening that could save lives.

France Breast Cancer Screening Market

France has a robust breast cancer screening initiative, with free mammography provided every two years for women aged 50-74. The French healthcare system emphasizes early detection, integrating AI and digital imaging. Continuous government efforts to improve awareness and participation rates contribute to market growth. March 2024, The Lunit company provides AI-powered solutions that can be used alongside cancer screenings and therapeutics. According to a press release,1 the deal will see Lunit providing the two territories with AI-powered radiology solutions that can be used with both chest x-rays and breast cancer detection.

United Kingdom Breast Cancer Screening Market

The UK’s National Health Service (NHS) provides free mammograms to women aged 50-70. The NHS Breast Screening Programme is one of the largest in Europe, and recent expansions include AI-assisted diagnostics to enhance detection rates. The increasing adoption of digital screening technologies strengthens the market. Feb 2025, The UK government has launched a major trial to assess the effectiveness of AI in improving early breast cancer detection. Led by the Department of Health and Social Care (DHSC), the initiative involves nearly 700,000 individuals being screened at 30 sites across England, utilizing AI technologies to enhance diagnosis accuracy and efficiency.

Netherlands Breast Cancer Screening Market

The Netherlands has a high participation rate in breast cancer screening, with government-funded programs covering women aged 50-75. Mobile screening units are widely used, improving access in rural areas. Dutch healthcare providers are increasingly adopting AI and personalized screening strategies, driving market growth. Oct 2023, Agendia NV, a leader in precision oncology for breast cancer, announced that the Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the national health insurance basic package. This decision is based on MINDACT study data, confirming that MammaPrint meets reimbursement criteria. The approval targets women over 50 with hormone-positive, HER2-negative breast cancer and 0-3 involved lymph nodes (clinical high risk), marking a significant advancement in personalized care for breast cancer patients in the Netherlands.

Europe Breast Cancer Screening Market Segments

Europe Breast Cancer Screening Market

• Mammography Screening Market
• MRI Screening Market
• Ultrasound Screening Market

Europe Breast Cancer Screening Population

• Mammography Screening Population
• MRI & Ultrasound Screening Population

Country-wise Analysis

• United Kingdom
• France
• Germany
• Italy
• Spain
• Switzerland
• Norway
• Netherlands

All the Key players have been covered from 5 Viewpoints:

• Overviews
• Key Person
• Recent Developments
• Product Portfolio     
• Revenue

Competitive Landscape

• AstraZeneca
• Novartis
• Sanofi
• Pfizer
• Bayer AG
• GlaxoSmithKline plc

Report Details: